Brainsway has announced that it has received a CE marketing approval, enabling it to immediately market and sell Brainsway deep TMS (deep transcranial magnetic stimulation) in Europe, for treatment of multiple sclerosis (MS), stroke and obsessive compulsive disorder (OCD).
These new indications join Brainsway’s numerous CE approvals for treating brain disorders, including autism, Alzheimer’s disease, bipolar disorder, chronic pain, major depressive disorder, Parkinson’s disease, post-traumatic stress disorder, schizophrenia (negative symptoms), and smoking cessation.
“We are glad to be able to bring light into the lives of more brain disorder patients,” says Shmulik Adler, vice president Business Development and Reimbursement, Brainsway. “The new CE approvals allow Brainsway deep TMS to provide an effective, safe and well-tolerated solution for the severe conditions of multiple sclerosis (MS), stroke and obsessive compulsive disorder (OCD). Brainsway intends to promote approval for these indications in additional markets in which we are active.”
